Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-996-5252
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees130
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its earnings results on Tuesday, August, 6th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.04. The business earned $2.06 million during the quarter, compared to analyst estimates of $2.62 million. View Kala Pharmaceuticals' Earnings History.
When is Kala Pharmaceuticals' next earnings date?
What price target have analysts set for KALA?
5 equities research analysts have issued 1 year price objectives for Kala Pharmaceuticals' stock. Their predictions range from $9.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $21.80 in the next year. This suggests a possible upside of 531.9% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.
What is the consensus analysts' recommendation for Kala Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.
Has Kala Pharmaceuticals been receiving favorable news coverage?
News coverage about KALA stock has trended negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Kala Pharmaceuticals.
Are investors shorting Kala Pharmaceuticals?
Kala Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,450,000 shares, an increase of 20.2% from the August 30th total of 2,870,000 shares. Based on an average daily volume of 315,200 shares, the days-to-cover ratio is currently 10.9 days. Approximately 13.5% of the company's stock are short sold. View Kala Pharmaceuticals' Current Options Chain.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Aptorum Group (APM), Akorn (AKRX), Retrophin (RTRX), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Lannett (LCI), INDIVIOR PLC/S (INVVY), Urogen Pharma (URGN), Progenics Pharmaceuticals (PGNX), Intra-Cellular Therapies (ITCI) and Myovant Sciences (MYOV).
What other stocks do shareholders of Kala Pharmaceuticals own?
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
- Mr. Todd Bazemore, Chief Operating Officer (Age 49)
- Dr. Kim Brazzell, Chief Medical Officer (Age 66)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $3.45.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $117.33 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.
What is Kala Pharmaceuticals' official website?
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
